[Skin lesions in a female patient with non-Hodgkin lymphoma].
Ducasse
Victoria Ortiz de la Tabla
VO
Sección de Microbiología, Hospital Universitario San Juan, Alicante, España.
Pintado
José Antonio Onrubia
JA
Gordon
Manuel Moragón
MM
Oyonarte
M Cristina Angeles
MC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000302:isolation & purification*; D001706:Biopsy; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003881:Dermatomycoses / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D012878:Skin Neoplasms / Q000175:diagnosis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003841:Deoxycytidine; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D011241:Prednisone; D000093542:Gemcitabine